Učitavanje...
Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose range 10–200 mg). A kinetic‐pharmacodynamic (K‐PD) model consisting of proliferation, maturation, and blood circulation c...
Spremljeno u:
| Izdano u: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577017/ https://ncbi.nlm.nih.gov/pubmed/32830463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12548 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|